BENGALURU (Reuters) - China's Shanghai Fosun Pharmaceutical Group Co Ltd has withdrawn plans to sell stake in Indian drugmaker Gland Pharma Ltd, ET Now tweeted on Wednesday, citing sources.
Fosun Pharma holds a 57.86% stake in the Indian company. Both Fosun Pharma and Gland Pharma did not immediately respond to Reuters' requests for comment.
Shares of Gland Pharma were up 0.8% at 1,360 rupees as of 9:50 a.m. IST. They have plunged 28% since November end, when Bloomberg News had reported, citing sources that Fosun Pharma was considering a sale of Gland Pharma after receiving interest from potential buyers.
(Reporting by Rama Venkat in Bengaluru; Editing by Rashmi Aich)
Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma
Indian pharma sector set for 'volume to value leadership' journey in 2023
Sun Pharma recalls over 34k bottles of generic drug in US due to mfg issues
Dr Reddy's, Sun Pharma recall products in US for manufacturing issues
Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report
TSLP reports Rs 184 cr loss in Q4 on account of increased expenses
Reckitt names Kris Licht as CEO, continues to beats sales estimates
Regional airline Fly91 receives govt approval, targets Oct launch
Chivas-maker Pernod challenges New Delhi licence rejection in court
S&P upgrades Tata Motors' long-term issuer, issue credit ratings to 'BB'
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)